VolitionRx Limited (NYSEAMERICAN:VNRX – Get Free Report) crossed above its fifty day moving average during trading on Thursday . The stock has a fifty day moving average of $0.00 and traded as high as $0.61. VolitionRx shares last traded at $0.56, with a volume of 291,323 shares traded.
VolitionRx Stock Performance
The stock has a market capitalization of $38.19 million, a PE ratio of -1.09 and a beta of 1.59.
VolitionRx (NYSEAMERICAN:VNRX – Get Free Report) last released its earnings results on Wednesday, August 14th. The medical research company reported ($0.08) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.09) by $0.01. VolitionRx had a negative net margin of 9,158.31% and a negative return on equity of 15,493.47%. The company had revenue of $0.40 million for the quarter, compared to the consensus estimate of $0.34 million. Equities research analysts expect that VolitionRx Limited will post -0.5 earnings per share for the current year.
About VolitionRx
VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.
Featured Articles
- Five stocks we like better than VolitionRx
- 3 Healthcare Dividend Stocks to Buy
- Battle of the Retailers: Who Comes Out on Top?
- What is the Nasdaq? Complete Overview with History
- HCA Healthcare: Temporary Setbacks, Long-Term Strength
- Natural Gas Prices Continue To Rally, These Stocks Should Benefit
- MarketBeat Week in Review – 10/28 – 11/1
Receive News & Ratings for VolitionRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VolitionRx and related companies with MarketBeat.com's FREE daily email newsletter.